Description

Orforglipron (LY3502970, OWL833) is a highly orally bioavailable small-molecule partial activator of the GLP-1 receptor. Through G-protein–coupled pathways, it replicates incretin effects while maintaining receptor sensitivity. Studies show it promotes improved body composition, metabolic balance, better glucose control, and enhanced beta-cell protection. It also helps balance cholesterol and inflammatory markers, contributing to cardiovascular and metabolic wellness. These findings suggest Orforglipron may play an important role in supporting overall metabolic efficiency and cellular resilience.